Citius Pharmaceuticals’ Lymphir and Keytruda Combo Shows Promising Clinical Outcomes, Earning a Buy Rating
Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Citius Pharmaceuticals (CTXR – Research Report). The ...
Citius Pharmaceuticals, Citius Oncology report promising cancer trial results
Citius Pharmaceuticals (CTXR) and Citius Oncology (CTOR) announced “promising” preliminary results from an ongoing ...